FRUTTERO, Roberta
FRUTTERO, Roberta
SCIENZA E TECNOLOGIA DEL FARMACO
A multitarget approach to optimize the safety profile of coxibs: lumiracoxib derivatives with dual cyclooxygenase-2 inhibitor-thromboxane A2 receptor antagonist activity
2013-01-01 Malvina Hoxha; Valerie Capra; Carola Buccellati; Angelo Sala; Mohammed Abrar Abdul Gaffar Shaikh; Clara Cena; Roberta Fruttero; Alberto Gasco; G. Enrico Rovati; Massimo Bertinaria
A New Synthetic Approach to Substituted β-Carboline Systems
1999-01-01 GIUSEPPE ERMONDI; SONJA VISENTIN; D. BOSCHI; ROBERTA FRUTTERO; ALBERTO GASCO
Amphiphile NO-donor antioxidants as polivalent drugs
2006-01-01 MARINI E; LAZZARATO L; CHEGAEV K; FRUTTERO R; GASCO A
Aspects of heterocyclic chemistry in developing new 1,4-dihydropyridine Ca2+-antagonists
2000-01-01 SONJA VISENTIN; GIUSEPPE ERMONDI; D. BOSCHI; ROBERTA FRUTTERO; ALBERTO GASCO
Aspects of heterocyclic chemistry in developing new 1,4-dihydropyridines Ca2+-agonists
2000-01-01 S.Visentin; G.Ermondi; D.Boschi; R. Fruttero; A. Gasco
Carnosine analogues containing Phenol substructures
2012-01-01 Giorgis M.; Bertinaria M.; Rolando B.; Montanaro G.; Fruttero R.; Gasco A.
Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives
2012-01-01 M. Bertinaria; M. A. A. G. Shaikh; C. Cena; B. Rolando; L. Lazzarato; R. Fruttero; A. Gasco; G. E. Rovati; C. Buccellati; V. Capra; A. Sala
Evaluation of the targeting ability of folate containing liposomal nitrooxy-doxorubicin.
2015-01-01 Pedrini, I.; Costamagna, F.; Buondonno, I.; Salaroglio, I. C.; Rolando, B.; Chegaev, K.; Fruttero, R.; Riganti, C.; Arpicco, S.
Hybrid praziquantel-oxadiazole oxides with activity against Schistosoma mansoni.
2011-01-01 Daniela Cortese; Francesca Vottero; Stefano Guglielmo; Roberta Fruttero; Alberto Gasco; Latasha Day and David L. Williams.
INCAPSULATED NO-GEMCITABINE: GASEOUS SOLUTION FOR MDR PANCREATIC CANCER
2019-01-01 Chegaev, K.; Masetto, F.; Gazzano, E.; Mullappily, N.; Rolando, B.; Donadelli, M.; Arpicco, S.; Riganti, C.; Fruttero, R.
Mechanism governing the partitioning of neutral and cationic forms of (p-methylbenzyl)(alkyl)amines in biomimetic media as revealed by lipophilicity and NMR studies
1997-01-01 ROBERTA FRUTTERO; ELISA FORNATTO; D. BOSCHI; GIUSEPPE ERMONDI; ALBERTO GASCO; GIULIA CARON; PIERRE-ALAIN CARRUPT; BERNARD TESTA
MODIFIED DOXORUBICINS: "GASEOUS APPROACH" TO OVERCOME CARDIOTOXICITY AND MULTIDRUG RESISTANCE
2016-01-01 Chegaev, K.; Rolando, B.; Gazzano, E.; Riganti, C.; Fruttero, R.
Monitoring patients with fragilities in the context of de-hospitalization services: An Ambient Assisted Living Healthcare Framework for e-Health applications
2019-01-01 Emilio Sulis, Ilaria Angela Amantea, Guido Boella, Clara Cena, Roberta Fruttero, Sara Traina, Pierluigi de Cosmo, Lucrezia Armando, Renata Marinello, Dario Bianca, Enrico Brunetti, Mario Bo, Alessandra Bianco, Francesco Cattel, Luca Carlo Feletti, Serena Ambrosini
Multitarget drugs: NO-donor doxorubicins
2012-01-01 Chegaev K.; Riganti C.; Rolando B.; Federico A.; Fruttero R.; Gasco A.
Multitarget Drugs: No-Donor Doxorubicins
2015-01-01 Chegaev, Konstantin; Riganti, Chiara; Gazzano, Elena; Rolando, Barbara; Fruttero, Roberta; Gasco, Alberto
New class of NO-donor soluble aspirins
2012-01-01 Marini E.; Rolando B.; Lazzarato L.; Joseph S.; Fruttero R.
NEW CLASS OF NO-DONORS WITH BONE SELECTIVITY
2003-01-01 L. LAZZARATO; LOLLI M.L; BALBO S; DELEIDE G; FRUTTERO R
New furoxan derivatives with Schistosomicidal activity.
2014-01-01 Daniela Cortese; David L. Williams; Peter D. Ziniel; Latasha Day; Stefano Guglielmo; Roberta Fruttero; Alberto Gasco.
New NO-donor Bisphosphonates
2001-01-01 L. LAZZARATO; LOLLI M.L; DI STILO A; FRUTTERO R; GASCO A
New potent and selective P-gp inhibitors
2013-01-01 Guglielmo S.; Bonomo S.; Colabufo N. A.; Contino M.; Perrone M. G.; Fruttero R.; Gasco A.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A multitarget approach to optimize the safety profile of coxibs: lumiracoxib derivatives with dual cyclooxygenase-2 inhibitor-thromboxane A2 receptor antagonist activity | 2013 | Malvina Hoxha; Valerie Capra; Carola Buccellati; Angelo Sala; Mohammed Abrar Abdul Gaffar Shaikh; Clara Cena; Roberta Fruttero; Alberto Gasco; G. Enrico Rovati; Massimo Bertinaria | |
A New Synthetic Approach to Substituted β-Carboline Systems | 1999 | GIUSEPPE ERMONDI; SONJA VISENTIN; D. BOSCHI; ROBERTA FRUTTERO; ALBERTO GASCO | |
Amphiphile NO-donor antioxidants as polivalent drugs | 2006 | MARINI E; LAZZARATO L; CHEGAEV K; FRUTTERO R; GASCO A | |
Aspects of heterocyclic chemistry in developing new 1,4-dihydropyridine Ca2+-antagonists | 2000 | SONJA VISENTIN; GIUSEPPE ERMONDI; D. BOSCHI; ROBERTA FRUTTERO; ALBERTO GASCO | |
Aspects of heterocyclic chemistry in developing new 1,4-dihydropyridines Ca2+-agonists | 2000 | S.Visentin; G.Ermondi; D.Boschi; R. Fruttero; A. Gasco | |
Carnosine analogues containing Phenol substructures | 2012 | Giorgis M.; Bertinaria M.; Rolando B.; Montanaro G.; Fruttero R.; Gasco A. | |
Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives | 2012 | M. Bertinaria; M. A. A. G. Shaikh; C. Cena; B. Rolando; L. Lazzarato; R. Fruttero; A. Gasco; G. E. Rovati; C. Buccellati; V. Capra; A. Sala | |
Evaluation of the targeting ability of folate containing liposomal nitrooxy-doxorubicin. | 2015 | Pedrini, I.; Costamagna, F.; Buondonno, I.; Salaroglio, I. C.; Rolando, B.; Chegaev, K.; Fruttero, R.; Riganti, C.; Arpicco, S. | |
Hybrid praziquantel-oxadiazole oxides with activity against Schistosoma mansoni. | 2011 | Daniela Cortese; Francesca Vottero; Stefano Guglielmo; Roberta Fruttero; Alberto Gasco; Latasha Day and David L. Williams. | |
INCAPSULATED NO-GEMCITABINE: GASEOUS SOLUTION FOR MDR PANCREATIC CANCER | 2019 | Chegaev, K.; Masetto, F.; Gazzano, E.; Mullappily, N.; Rolando, B.; Donadelli, M.; Arpicco, S.; Riganti, C.; Fruttero, R. | |
Mechanism governing the partitioning of neutral and cationic forms of (p-methylbenzyl)(alkyl)amines in biomimetic media as revealed by lipophilicity and NMR studies | 1997 | ROBERTA FRUTTERO; ELISA FORNATTO; D. BOSCHI; GIUSEPPE ERMONDI; ALBERTO GASCO; GIULIA CARON; PIERRE-ALAIN CARRUPT; BERNARD TESTA | |
MODIFIED DOXORUBICINS: "GASEOUS APPROACH" TO OVERCOME CARDIOTOXICITY AND MULTIDRUG RESISTANCE | 2016 | Chegaev, K.; Rolando, B.; Gazzano, E.; Riganti, C.; Fruttero, R. | |
Monitoring patients with fragilities in the context of de-hospitalization services: An Ambient Assisted Living Healthcare Framework for e-Health applications | 2019 | Emilio Sulis, Ilaria Angela Amantea, Guido Boella, Clara Cena, Roberta Fruttero, Sara Traina, Pierluigi de Cosmo, Lucrezia Armando, Renata Marinello, Dario Bianca, Enrico Brunetti, Mario Bo, Alessandra Bianco, Francesco Cattel, Luca Carlo Feletti, Serena Ambrosini | |
Multitarget drugs: NO-donor doxorubicins | 2012 | Chegaev K.; Riganti C.; Rolando B.; Federico A.; Fruttero R.; Gasco A. | |
Multitarget Drugs: No-Donor Doxorubicins | 2015 | Chegaev, Konstantin; Riganti, Chiara; Gazzano, Elena; Rolando, Barbara; Fruttero, Roberta; Gasco, Alberto | |
New class of NO-donor soluble aspirins | 2012 | Marini E.; Rolando B.; Lazzarato L.; Joseph S.; Fruttero R. | |
NEW CLASS OF NO-DONORS WITH BONE SELECTIVITY | 2003 | L. LAZZARATO; LOLLI M.L; BALBO S; DELEIDE G; FRUTTERO R | |
New furoxan derivatives with Schistosomicidal activity. | 2014 | Daniela Cortese; David L. Williams; Peter D. Ziniel; Latasha Day; Stefano Guglielmo; Roberta Fruttero; Alberto Gasco. | |
New NO-donor Bisphosphonates | 2001 | L. LAZZARATO; LOLLI M.L; DI STILO A; FRUTTERO R; GASCO A | |
New potent and selective P-gp inhibitors | 2013 | Guglielmo S.; Bonomo S.; Colabufo N. A.; Contino M.; Perrone M. G.; Fruttero R.; Gasco A. |